Text Size

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma

This study has been completed.
Sponsor:
Information provided by:
Alcon Research
ClinicalTrials.gov Identifier:
NCT00051181
First received: January 3, 2003
Last updated: August 4, 2008
Last verified: August 2008
History of Changes
  Purpose

To demonstrate that the intraocular pressure(IOP)-lowering efficacy of Travoprost (0.004%) is equal or better than that of Latanoprost 0.005% in patients with chronic angle-closure glaucoma.


Condition Intervention Phase
Glaucoma, Angle-Closure
Ocular Hypertension
 Drug: Travoprost (0.004%)
Drug: Latanoprost (0.005%)
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma.

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Alcon Research:

Study Start Date: January 2000
Study Completion Date: June 2003
Primary Completion Date: June 2003 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Adult patients of any race and either sex with chronic angle-closure glaucoma.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00051181

Locations
United States, Texas
Asia
Fort Worth, Texas, United States
Australia
Australia
Sidney, Australia
Sponsors and Collaborators
Alcon Research
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00051181     History of Changes
Other Study ID Numbers: C-01-38
Study First Received: January 3, 2003
Last Updated: August 4, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by Alcon Research:
Glaucoma
POAG
OAG
OHT

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Angle-Closure
Hypertension
Ocular Hypertension
Eye Diseases
Vascular Diseases
Cardiovascular Diseases
 Latanoprost
Travoprost
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 22, 2013